Harnessing the microbiome
to improve health
Osel, Inc. is pioneering a new class of medicine called Live Biotherapeutic Products that modulate the body’s natural microbiome to restore health and prevent infection.
MOUNTAIN VIEW, CA (July 21, 2016): Osel, Inc. today commented on findings presented by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers at the International AIDS 2016 Conference, detailing the role played by vaginal dysbiosis in the high rates of sexual transmission of HIV to women from men.read more
Osel, Inc.’s Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
Mountain View, CA (May 11, 2016): Osel, Inc. today announced the initiation of a Phase 2b clinical study of its lead product candidate, LACTIN-V, to prevent the recurrence of bacterial vaginosis following antibiotic therapy.read more
The article delves into the rapidly expanding sector of companies aiming to alter a native microbiome for therapeutic purposes, noting that microbiome players raised more than $300 million in funding in 2015 alone, a dramatic increase over previous years.read more